HCW Biologics Inc Market Cap ($2.06 Million)
Market Cap & Net Worth: HCW Biologics Inc (HCWB)
HCW Biologics Inc market cap. HCW Biologics Inc (NASDAQ:HCWB) has a market capitalization of $2.06 Million ($2.06 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30016 globally and #6129 in its home market, demonstrating a -4.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HCW Biologics Inc's stock price $1.12 by its total outstanding shares 1836324 (1.84 Million). Also see HCW Biologics Inc (HCWB) cash flow conversion for how efficiently the company converts equity into cash flow.
HCW Biologics Inc Market Cap History (2021–2026)
HCW Biologics Inc market cap history from 2021 to 2026. Data shows change from $4.26 Million to $2.06 Million (-27.85% CAGR). Check today's stock price for HCW Biologics Inc for real-time trading data and today's change.
Index Memberships
HCW Biologics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #870 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2779 of 3165 |
Weight: HCW Biologics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HCW Biologics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HCW Biologics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is HCW Biologics Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
32.87x
HCW Biologics Inc's market cap is 32.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $4.26 Million | $4.10 Million | -$12.86 Million | 1.04x | N/A |
| 2022 | $3.52 Million | $6.72 Million | -$14.90 Million | 0.52x | N/A |
| 2023 | $2.25 Million | $2.84 Million | -$24.99 Million | 0.79x | N/A |
| 2024 | $819.18K | $2.57 Million | -$30.02 Million | 0.32x | N/A |
| 2025 | $1.78 Million | $54.23K | -$7.96 Million | 32.87x | N/A |
Competitor Companies of HCWB by Market Capitalization
Companies near HCW Biologics Inc in the global market cap rankings as of November 4, 2026. Also see HCWB asset base for a full breakdown of the balance sheet.
Key companies related to HCW Biologics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of HCW Biologics Inc (2021–2026)
Market capitalization of HCW Biologics Inc from 2021 to today. Between 2021 and today, HCW Biologics Inc's market cap moved from $4.26 Million to $ 2.06 Million, with a yearly change of -27.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.06 Million | +15.39% |
| 2025 | $1.78 Million | +117.57% |
| 2024 | $819.18K | -63.58% |
| 2023 | $2.25 Million | -36.03% |
| 2022 | $3.52 Million | -17.46% |
| 2021 | $4.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of HCW Biologics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.06 Million USD |
| MoneyControl | $2.06 Million USD |
| MarketWatch | $2.06 Million USD |
| marketcap.company | $2.06 Million USD |
| Reuters | $2.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more